Gastro-enteropancreatic Neuroendocrine Tumor - 18 Studies Found
| Completed |
: A Study of Famitinib in Patients With Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumor : Gastroenteropancreatic Neuroendocrine Tumor : 2013-11-19 : Drug: Famitinib Famitinib 25 mg p.o. qd |
| Terminated |
: Diagnostic Accuracy of Gallium-68-DOTATATE PET/CT Compared to Indium-111-pentetreotide Scintigraphy (SPECT/CT) for Gastroenteropancreatic Neuroendocrine Tumors : Gastroenteropancreatic Neuroendocrine Tumors : 2014-02-26 :
|
| Not yet recruiting |
: Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors : Gastroenteropancreatic Neuroendocrine Tumors : 2017-02-01 :
|
| Completed |
: Lanreotide and Octreotide Long Acting Release (LAR) for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) : Gastroenteropancreatic Neuroendocrine Tumor : 2016-12-30 |
| Completed |
: TEP With 68-DOTANOC in Gastroenteropancreatic Neuroendocrine Tumors : Patients With Gastroenteropancreatic Neuroendocrine Tumors : 2012-11-13 : Drug: 68-Ga-DOTANOC |
| Completed |
: Quality of Life, Treatment Experience and Cost of Treatment With Somatostatin Analogues in Patients With Gastroenteropancreatic Neuroendocrine Tumours : Gastroenteropancreatic Neuroendocrine Tumours : 2016-05-27 |
| Not yet recruiting |
: [68 Ga]-DOTANOC PET/CT in GEP-NETs : Gastroenteropancreatic Neuroendocrine Tumors : 2015-11-09 : Drug: [68Ga]-DOTANOC PET/CT |
| Completed |
: Community-based Neuroendocrine Tumor (NET) Research Study : Gastroenteropancreatic Neuroendocrine Tumors : 2016-04-01 |
| Withdrawn |
: Pasireotide Treatment for Neuroendocrine Tumor : Gastro-enteropancreatic Neuroendocrine Tumor : 2016-05-16 :
|
| Completed |
: Study For Evaluating The Value Of A Multi Biomarker Approach In Metastatic GEP NETs : Gastroenteropancreatic Neuroendocrine Tumors : 2015-12-11 : Other: This is a non-interventional study. Patients will be treated with any intervention deemed appropriate by the patient's physician. |